BR112022016803A2 - População de linfócitos e métodos para produzir os mesmos - Google Patents
População de linfócitos e métodos para produzir os mesmosInfo
- Publication number
- BR112022016803A2 BR112022016803A2 BR112022016803A BR112022016803A BR112022016803A2 BR 112022016803 A2 BR112022016803 A2 BR 112022016803A2 BR 112022016803 A BR112022016803 A BR 112022016803A BR 112022016803 A BR112022016803 A BR 112022016803A BR 112022016803 A2 BR112022016803 A2 BR 112022016803A2
- Authority
- BR
- Brazil
- Prior art keywords
- lymphocytes
- methods
- population
- produce
- diseases
- Prior art date
Links
- 210000004698 lymphocyte Anatomy 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/418—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Developmental Biology & Embryology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062983005P | 2020-02-28 | 2020-02-28 | |
| US202063009050P | 2020-04-13 | 2020-04-13 | |
| US202063123054P | 2020-12-09 | 2020-12-09 | |
| PCT/US2021/019773 WO2021173900A1 (en) | 2020-02-28 | 2021-02-26 | Lypmphocyte population and methods for producing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022016803A2 true BR112022016803A2 (pt) | 2022-11-08 |
Family
ID=75108879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022016803A BR112022016803A2 (pt) | 2020-02-28 | 2021-02-26 | População de linfócitos e métodos para produzir os mesmos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230096897A1 (enExample) |
| EP (1) | EP4110902A1 (enExample) |
| JP (1) | JP2023514788A (enExample) |
| KR (1) | KR20220148859A (enExample) |
| CN (1) | CN115516085A (enExample) |
| AU (1) | AU2021227925A1 (enExample) |
| BR (1) | BR112022016803A2 (enExample) |
| CA (1) | CA3168378A1 (enExample) |
| IL (1) | IL295952A (enExample) |
| MX (1) | MX2022010674A (enExample) |
| WO (1) | WO2021173900A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230172950A1 (en) * | 2020-04-29 | 2023-06-08 | Avm Biotechnology, Llc | Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus |
| EP4395784A1 (en) * | 2021-09-01 | 2024-07-10 | AVM Biotechnology, LLC | Lymphocyte population and methods for producing same |
| CN114561362B (zh) * | 2021-12-28 | 2023-12-15 | 江西省疾病预防控制中心 | 一种人源肾综合征出血热汉坦病毒分离方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2073009A1 (en) * | 2007-12-19 | 2009-06-24 | Cell Med Research GMBH | Method for T, NK and NKT cells |
| WO2012074116A1 (ja) * | 2010-12-02 | 2012-06-07 | 独立行政法人理化学研究所 | アロNKT細胞を用いた免疫療法およびそのためのT細胞抗原受容体（TCR）遺伝子のα鎖領域が均一なVα-Jαに再構成されている細胞および該細胞由来NKT細胞のバンキング |
| WO2015112793A2 (en) * | 2014-01-27 | 2015-07-30 | St. Jude Children's Research Hospital, Inc. | Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof |
| EP3490605B1 (en) * | 2017-04-01 | 2023-06-07 | AVM Biotechnology, LLC | Replacement of cytotoxic preconditioning before cellular immunotherapy |
| CA3106056A1 (en) * | 2018-07-26 | 2020-01-30 | Ospedale Pediatrico Bambino Gesu (Opbg) | Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use |
| CN113286811B (zh) * | 2018-07-30 | 2024-12-06 | 南加利福尼亚大学 | 改善过继性细胞疗法的效力和安全性 |
| EP3488851A1 (en) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
-
2021
- 2021-02-26 CA CA3168378A patent/CA3168378A1/en active Pending
- 2021-02-26 EP EP21713284.4A patent/EP4110902A1/en active Pending
- 2021-02-26 IL IL295952A patent/IL295952A/en unknown
- 2021-02-26 US US17/801,293 patent/US20230096897A1/en active Pending
- 2021-02-26 AU AU2021227925A patent/AU2021227925A1/en active Pending
- 2021-02-26 JP JP2022551251A patent/JP2023514788A/ja active Pending
- 2021-02-26 KR KR1020227033562A patent/KR20220148859A/ko active Pending
- 2021-02-26 CN CN202180028199.7A patent/CN115516085A/zh active Pending
- 2021-02-26 BR BR112022016803A patent/BR112022016803A2/pt unknown
- 2021-02-26 WO PCT/US2021/019773 patent/WO2021173900A1/en not_active Ceased
- 2021-02-26 MX MX2022010674A patent/MX2022010674A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021173900A1 (en) | 2021-09-02 |
| CN115516085A (zh) | 2022-12-23 |
| IL295952A (en) | 2022-10-01 |
| CA3168378A1 (en) | 2021-09-02 |
| MX2022010674A (es) | 2022-11-30 |
| AU2021227925A1 (en) | 2022-09-15 |
| EP4110902A1 (en) | 2023-01-04 |
| JP2023514788A (ja) | 2023-04-10 |
| KR20220148859A (ko) | 2022-11-07 |
| US20230096897A1 (en) | 2023-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022016803A2 (pt) | População de linfócitos e métodos para produzir os mesmos | |
| BR112022015416A2 (pt) | Anticorpos anti-ror1 e composições | |
| CL2019000485A1 (es) | Uso de pridopidina para el tratamiento de la disminución funcional. | |
| CL2022000368A1 (es) | Usos terapéuticos de anticuerpos anti-variable delta 1 de tcr | |
| CR20200334A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| CO2026004333A2 (es) | Inhibidores de ras-pi3k para el tratamiento del cáncer y enfermedades inmunológicas | |
| BR112022027101A2 (pt) | Anticorpos multiespecíficos que se ligam a bcma | |
| CR20250081A (es) | Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso | |
| MX2024004119A (es) | Composiciones y metodos para el tratamiento de enfermedades de repeticion cag | |
| CO2021004681A2 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| CO2021015793A2 (es) | Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33 | |
| CL2022000786A1 (es) | Metodos de tratamiento para modificar la hemodinamica | |
| MX2022014199A (es) | Usos y formulaciones de los cannabinoides. | |
| MX2023000164A (es) | Métodos y composiciones para tratar la hemofilia. | |
| DOP2022000058A (es) | Anticuerpos contra el factor de las células madre y métodos de uso de ellos | |
| CR20220374A (es) | Métodos de tratamiento de la esplenomegalia | |
| BR112023010891A2 (pt) | Compostos polipeptídicos modificados com lactama | |
| CO2023015982A2 (es) | Anticuerpos anti-nkg2a y composiciones | |
| ZA202300222B (en) | Anti-αlpha-4-βeta-7 antibodies | |
| CO2022015018A2 (es) | Métodos y medios para modificar la hemodinámica en infecciones | |
| DOP2025000286A (es) | Composiciones para tratae la pérdida de audición y/o la pérdida de visión asociada a clrn1 | |
| JOP20200151A1 (ar) | طريقة تصنيع صفيحة تجديد جلد خاص بمريض قدم سكرية وصفيحة تجديد جلد خاص بمريض قدم سكرية مصنعة باستخدام الطريقة ذاتها | |
| BR112021019876A2 (pt) | Inibidores de pde9 para tratar anemia falciforme | |
| BR112022016326A2 (pt) | Anticorpo anti-il-2, e fragmento de ligação ao antígeno do mesmo e uso médico do mesmo | |
| CL2023002236A1 (es) | Métodos para tratar la amiloidosis primaria |